Thomas Ciulla - 21 Sep 2021 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
Chief Medical Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
CLSD
Transactions as of
21 Sep 2021
Net transactions value
-$16,384
Form type
4
Filing time
23 Sep 2021, 17:17:49 UTC
Next filing
28 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Sale $16,384 -2,560 -0.99% $6.40* 255,560 21 Sep 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
F2 Includes 4,998 shares acquired under the Issuer's employee stock purchase plan on June 30, 2021.